Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SNGX by emailGet an email when SNGX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SNGX, unsubscribe in one click. Privacy
📣 What SNGX Says Is Next
in 2026 · “With these results, we intend to embark on a reformulation of SGX945 to enable home-based treatment and look forward to interacting with the health authorities in designing a follow-on placebo-controlled Phase 2b study in 2026.”
Company press release, Feb 12, 2026 · SEC filing
second half of 2026 · “Top-line results from the actively enrolling 80 patient confirmatory Phase 3 FLASH 2 ( F luorescent L ight A nd S ynthetic H ypericin 2 ) clinical trial for HyBryte™ (SGX301 or synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (CTCL) are expected in the second half of 2026, with an interim analysis fast approaching in 2Q.”
Company press release, Feb 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SNGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.